Drugs that contain Lurbinectedin

1. List of Zepzelca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7763615 JAZZ Ecteinascidin analogs for use as antitumour agents
Dec, 2024

(1 year, 6 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 15, 2025
Orphan Drug Exclusivity (ODE) Jun 15, 2027

NCE-1 date: 2024-06-15

Market Authorisation Date: 15 June, 2020

Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ZEPZELCA family patents

3

European Union

2

United Kingdom

2

Japan

1

Poland

1

Canada

1

Slovenia

1

Korea, Republic of

1

Hong Kong

1

China

1

Germany

1

Denmark

1

Hungary

1

Spain

1

Mexico

1

New Zealand

1

Australia

1

Norway

1

United States

1

Austria

1

Portugal

1

Russia

1

Israel

1

Cyprus

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in